GENFIT Achieves B Corp Certification, Advances ACLF Ecosystem Engagement
Event summary
- GENFIT published its 2026 Extra-Financial Report for fiscal year 2025, highlighting 30 ESG initiatives involving all employees.
- The company achieved B Corp certification in 2025, reinforcing its commitment to ethical practices and stakeholder trust.
- ACLF (Acute on-chronic Liver Failure) was formally recognized as a strategic area by The Forum for Collaborative Research.
- Employee engagement survey showed 90% participation with high satisfaction levels across all criteria.
- Gender equality index remained high at 88, consistent with the previous year.
The big picture
GENFIT's 2026 Extra-Financial Report underscores its strategic focus on ESG initiatives and stakeholder engagement, aligning with broader industry trends toward ethical governance and patient-centric innovation. The company's B Corp certification and ACLF ecosystem engagement reflect its commitment to addressing unmet medical needs in rare liver diseases. With Ipsen as a significant shareholder, GENFIT's efforts to balance financial performance with societal impact will be closely watched by investors and analysts.
What we're watching
- ESG Execution
- Whether GENFIT can sustain the momentum of its ESG roadmap and maintain B Corp certification.
- ACLF Advocacy
- The pace at which GENFIT can mobilize the medical and regulatory ecosystem to prioritize ACLF.
- Operational Efficiency
- How GENFIT's deployment of AI and cyber risk management will impact its productivity and operational efficiency.
Related topics